# Suppression of har-1/CHCHD10 phenotypes for ALS-FTD therapy discovery

## TL;DR

This study explores using a worm model to find therapies for ALS-FTD by testing compounds that alleviate disease-related symptoms.

## Contribution

The study introduces a novel worm model for ALS-FTD and identifies potential therapeutic agents.

## Key findings

- Pioglitazone and Lacticaseibacillus rhamnosus HA-114 reduce har-1 mutant phenotypes in worms.
- The har-1 model is suitable for modifier and drug screening studies for ALS-FTD.
- The model supports high-throughput screening and microbiome research for therapeutic discovery.

## Abstract

Mutations in
CHCHD10
are linked to a variety of neurodegenerative diseases, including amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). The

Caenorhabditis elegans

orthologue of
CHCHD10
is

har-1
,

and we investigated whether

har-1

mutants could be used for therapeutic discovery in ALS-FTD. Our results show that the small molecule pioglitazone and the probiotic
Lacticaseibacillus rhamnosus
HA-114 can alleviate

har-1

mutant phenotypes. These findings suggest that

har-1

mutants are suitable for modifier screens and could be adapted for high-throughput drug screening and microbiome studies to aid in discovering therapies for ALS-FTD.